These innovative agents represent a significant leap in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose levels. https://monicajsyl325874.madmouseblog.com/19796420/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide